40 Cities with the Lowest Life Expectancy in the US

In This Article:

In this article, we look at 40 cities with the lowest life expectancy in the US. You can skip our section on developments in the pharmaceutical and biotech industries to enhance longevity and head over directly to 10 Cities with the Lowest Life Expectancy in the US.

Average lifespan in the US climbed from just 47 years in 1900 to nearly 79 in 2019 before the coronavirus pandemic struck. After that, it saw a decline for two consecutive years, driven by increased cases of drug overdose and effects of Covid-19 according to a report by Harvard University. Life expectancy in the US plunged to 77 years in 2020, before further slumping to 76 years in 2021. However, in 2022, expectancy rebounded to 77.5 years, according to the Centers for Disease Control and Prevention (CDC).

Despite the fluctuations, life expectancy in the US is still well higher than the global average which is 71 years. This is due to the general advancement in research and development in America’s pharmaceutical sector, and the surge of biotechnology companies in the country that are producing drugs which are proving effective in battling life-threatening diseases.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotechnology in Salt Lake City, Utah, uses artificial intelligence to reinvent drug discovery by decoding biology and integrating it with advancements in various other areas such as chemistry, data science, and machine learning. The main aim of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is to speed up pharmaceutical development by producing an AI platform that lowers the time and cost spent on drug development. This year, German pharmaceutical firm, Bayer AG, announced that it was pledging $1.5 billion to work on seven oncology and cancer treatment related projects with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX).

Biophytis S.A. (NASDAQ:BPTS) on the other hand specializes in developing therapeutics to slow down the degenerative processes that are associated with aging and improve the health of patients that are suffering with severe respiratory diseases. Biophytis S.A. (NASDAQ:BPTS)’s most advanced clinical program currently in development is Sarconeos (BIO101), a lead drug candidate for the treatment of neuromuscular diseases.

Based on tests performed during animal and cellular studies, according to Biophytis S.A. (NASDAQ:BPTS), Sarconeos activates MAS receptors that stimulate biological resilience through improved muscle function. In May 2023, it was reported that Biophytis S.A. (NASDAQ:BPTS) was gearing up for phase III of Sarconeos trial in the EU, in which the company would evaluate the safety and effectiveness of the drug on patients of sarcopenia who are at risk of mobility disability.